Firefly Neuroscience Inc.

fireflyneuro.com

Formerly elminda

High-Tech Company
Public Company

(NASDAQ CM: AIFF)

TECH VERTICALS

Neuroscience ADHD, Analytics, Artificial Intelligence, Big Data, BrainTech, Diagnostics, Digital Health, Discovery, Healthtech, Imaging, Life Sciences, Machine Learning, Medical Devices, MedTech, Mental Health, Neurology, Non Invasive, Performance Enhancement, Psychiatry, Research, SportsTech

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	2006
Number of Employees	25
Employees in Israel	12
Reg. Number:	abCDe

DESCRIPTION

Firefly is an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.

TECHNOLOGY

BNA™ (Brain Network Analytics): Electro-physiology functional brain mapping, imaging and monitoring.

Products and Phases

Product	Phase
BNA™	FDA Approved CE Approved
BNA™ (Brain Network Analytics) utilizes artificial intelligence and a proprietary database to analyze electroencephalogram (EEG) data. The technology compares patients’ EEG readings at rest and during activity to normative data, identifying unique brain patterns and deviations to assist in brain health evaluation and clinical decision making.

	TARGET MARKETS
	Clinicians, Pharmaceutical companies, Neurology and Psychiatry markets (concussion, stroke, pain management, ADHD, depression, etc.), Rehabilitation Centers.

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Buffalo, United States

Address	1100 Military Rd.
City	Buffalo
State/Province	NY
Country	United States
Zip	14217

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Herzliya, Israel

Address	14 Maskit St.
POB	12941
City	Herzliya
Country	Israel
Zip	4673314

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Jon Olsen	CEO
Mr. Paul Kryzwicki	CFO
Dr. Samer Kaba	Chief Medical Officer
Mr. Gil Issachar	CTO
Mr. Jason DuBraski	VP, Sales
Prof. Amir Geva	Co-Founder
Dr. Goded Shahaf	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Executive Chairman	Managing Director, Old Stone Advisors
abC Defghij	Board Member	CEO, Firefly
abC Defghij	Board Member	Co-Founder, ClosedLoop.ai.
abC Defghij	Board Member	CEO, Likarda Biotech; Founder, OralBioLife, Dialysis Biosciences & ACG Group
abC Defghij	Board Member	Former CFO, electroCore Inc.
abC Defghij	Board Member	CEO, Profound Medical Inc.

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Nov. 16, 2023

Initial Revenues

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Feb. 21, 2025

Initial Revenues

abCDe

PIPE

Dec. 31, 2024

Initial Revenues

abCDe

Debt Financing

Dec. 31, 2024

Initial Revenues

abCDe

PIPE

Aug. 12, 2024

Initial Revenues

abCDe

Third Round

Nov. 16, 2015

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Hedge Fund	abCDe
abC Defghij	Angel Club/ Group	abCDe
abC Defghij	Family Office	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Angel Syndicate	abCDe
abC Defghij	Consulting Firm	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Investment Bank	abCDe

Second Round

Jun. 01, 2012

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Angel Club/ Group	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

First Round

Sep. 04, 2008

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Angel Club/ Group	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Seed

Mar. 01, 2006

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Angel Club/ Group	abCDe
abC Defghij	Technology Transfer Company	abCDe	BGN received equity in the company in exchange for providing technology & IP.
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2019

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Mar. 31, 2019

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Fund	abCDe

R&D Grant

Jun. 01, 2018

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe